AST-301 + sargramostim

**AST-301 + sargramostim** is a combination therapy consisting of AST-301, a plasmid DNA-based therapeutic cancer vaccine encoding the intracellular domain of HER2, and sargramostim, a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF)[3][7]. AST-301 acts by stimulating adaptive immune responses against HER2-expressing tumor cells, leveraging vaccine-induced activation of cytotoxic T-lymphocytes and helper T cells[1][3]. Sargramostim acts as an immune adjuvant, promoting immune cell recruitment and activation, and is frequently used to enhance vaccine immunogenicity in cancer therapy[7]. This combination targets HER2-expressing tumors, especially in gastric and breast cancer, and aims to optimize the anti-tumor immune response and hematologic recovery post-cancer therapy[1][3][6].

Other names

recombinant human GM-CSFsargramostimAST-301AST301AST 301